Announcements Trials
Browse Landscape

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Nasopharyngeal Carcinoma 39Carcinoma, Non-Small-Cell Lung 30Esophageal Squamous Cell Carcinoma 23Carcinoma, Hepatocellular 23Triple Negative Breast Neoplasms 19Breast Neoplasms 18Squamous Cell Carcinoma of Head and Neck 17Advanced Solid Tumor 17Melanoma 15Stomach Neoplasms 14Small Cell Lung Carcinoma 13Colorectal Neoplasms 13Uterine Cervical Neoplasms 12Neoplasms 10Carcinoma, Transitional Cell 10Carcinoma, Renal Cell 10Recurrence 9Head and Neck Neoplasms 8Solid Tumor 7Sarcoma 7Neoplasm Metastasis 7Liver Neoplasms 7Esophageal Neoplasms 6Urinary Bladder Neoplasms 5Rectal Neoplasms 5Advanced Solid Tumors 5Pancreatic Neoplasms 4Nasopharyngeal Neoplasms 4Laryngeal Neoplasms 4Hypopharyngeal Neoplasms 4

Interventions

HMPL-013 2toripalimab 1tislelizumab 1sintilimab 1regorafenib 1raltitrexed 1pembrolizumab 1camrelizumab 1Nivolumab 1Drug Therapy 1Capecitabine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Colorectal Carcinoma × toripalimab × Clear all
NCT04771715 2021-02-25

Regorafenib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Patients With Advanced Colorectal Cancer

Peking Union Medical College Hospital

Unknown
100 enrolled
Gastrointestinal

Advanced Colorectal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡